Utilization of thymine analogue as a boron carrier for neutron capture therapy

The BNCT effect of 5'- carboranyl uridine (5'-CU), one of a most powerful candidate of thymine analogues as a boron carrier, was investigated on experimental brain tumor models. 5'-CU was highly accumulated into tumor cells through its multi-affinity potential to a variety of subcellular fractions of DNA/RNA and proteins. The boron concentration in tumor was more than 100 ppm, and its tumor/normal brain ratio was more than 11. Thermal neutron dose yielding 37% surviving fraction on cultured glioma cells was 3.7x1012 nvt which was lower than that of control dose of 5.8x1012 nvt. However, α-autoradiogram revealed that 5'-CU tightly binded to a variety of normal brain structures; choloid plexus, ependymal layer and so on. Indeed, the mean surviving fraction of brain tumor rats after BNCT using 5'-CU was slightly lower than that of control rats which did not received neutrons and 5'-CU. Furthermore its cytotoxicity was not low enough, 1/10-1/20 dose of rat LD50 was required as a therapeutic dose. We are now under investigation of its clinical applicability as a boron carrier through its chemical modification in order to circumvent those problems, or warrant of further experiments in this area. (author)